Paul Miranda, MD

Board-Certified in Family Medicine · Emergency Physician · Obesity Medicine Association member

I’m an emergency and Family Medicine physician in Chattanooga, Tennessee, and founder of Summit Metabolic Health. I read every patient chart personally. This article reports on a topic patients keep asking about — it is education, not an endorsement.

Medically reviewed by Paul Miranda, MD

If you’re in Chattanooga typing “is telehealth semaglutide legit” into Google at 11pm, you’ve probably already seen three landing pages that all look identical: a stock photo, a questionnaire, a checkout button. I’m Paul Miranda, a board-certified physician practicing telehealth from right here in Chattanooga, and I personally review every chart before a patient starts semaglutide at Summit Metabolic Health. The question you’re actually asking isn’t about the drug. It’s about who’s watching what happens after you take it.

Nobody searches this phrase because they doubt semaglutide works. The trial data is public and it’s strong. They search it because the intake process felt wrong — a form that approved them in ninety seconds, a price that quietly changed on month two, a “provider” they’ve never spoken to and never will. That instinct is correct. It’s just aimed at the wrong target. The drug isn’t the risk. The absence of a doctor watching your chart is.

Ro, Hims, and Found all built the same basic funnel: answer a questionnaire, get algorithm-routed to a clinician for a same-day approval, then move into an NP-staffed follow-up queue where you rarely see the same name twice. That’s not automatically dangerous. It’s just not what “legit” should mean for a medication this powerful, and the platforms selling it have every incentive to let the word do work it hasn’t earned.

Here’s the honest answer: legitimacy isn’t a badge, a certification seal, or a “board-certified doctors on staff” line in the footer. It’s three concrete things you can actually verify.

First, a named prescriber who reads your specific chart before every dose change — not an algorithm-generated recommendation a clinician rubber-stamps in bulk across hundreds of patients a day. Second, a real chart that follows you visit to visit, so your labs, your side effects, and your dose history are in one place a physician actually opens, instead of a new intake form each time you log back in. Third, if you’re on compounded medication, a licensed pharmacy you can identify by name, not a sourcing chain buried three vendors deep behind a shipping label. I wrote the longer version of that third point, including what “compounded” should and shouldn’t mean to a patient, in Is Compounded Semaglutide Safe? A Chattanooga Physician Explains.

Miss any one of those three, and the rest of the marketing — the app, the reviews, the founder story — doesn’t matter. You’re not getting managed care. You’re getting a subscription with a prescription attached to it.

Hims built a large share of its GLP-1 growth on compounded semaglutide, priced well under branded Wegovy or Ozempic. Earlier this year, a public compounding-sourcing controversy put that pricing model under real scrutiny, and Hims pulled back from compounded GLP-1s entirely. Patients who’d started on the promotional rate got shifted onto branded medication, and for a lot of them the all-in monthly cost now runs close to $450 once the introductory period ends.

That’s not a story about one bad vendor. It’s what happens structurally when the business model is intake-and-ship at scale: the sourcing decision gets made by a growth team optimizing for margin, not by a physician evaluating what’s right for your chart. When the sourcing changed, the patient found out from an invoice, not a doctor. Nobody called to explain the switch, walk through what changed in the medication, or ask whether the new price still worked for their budget. I go deeper on what that pricing cliff actually looks like, and what to check for with any national platform, in Hims Alternatives for Semaglutide: Physician-Led Care in Chattanooga.

Here’s where I’d push back on the framing most comparison pages use. They treat the trial data as proof the drug is safe enough to sell through an app. Read the actual numbers and they argue the opposite.

STEP 1 showed patients on semaglutide lost a mean 14.9% of body weight at 68 weeks, against 2.4% on placebo (Wilding et al., NEJM, 2021). SELECT went further: in overweight or obese adults with established cardiovascular disease, semaglutide cut major adverse cardiac events by 20% (Lincoff et al., NEJM, 2023). Those aren’t small effects. A drug that changes appetite, slows gastric emptying, and measurably shifts cardiac risk at that scale is not a drug you dose-titrate by algorithm. It’s a drug where someone needs to be watching your blood pressure, your GI tolerance, and your cardiac history as the dose climbs — and adjusting when your body tells them to slow down.

That’s the actual definition of “legit” worth checking for. Not a seal on a landing page. A named prescriber whose job is to notice when the trial-average patient and the patient in front of them stop matching. I laid out the fuller contrast between that model and the intake-and-ship one in Physician-Supervised vs. Telehealth Mill: What’s the Real Difference?

Care at Summit is telehealth — but the physician running it lives and works in Chattanooga, not a call center three time zones away. I read every chart myself before a dose changes. There’s no NP queue standing between you and the person making the decision, and no questionnaire deciding your dose for you.

Pricing is flat and published: $149/month during active treatment, $99/month once you reach maintenance, with medication itemized separately through Summit’s licensed compounding pharmacy so you know exactly what you’re paying for the visit versus the drug. No promotional rate built to expire, no invoice that quietly triples. That matters more now, with grocery chains like Kroger and pharmacy counters like CVS starting to bolt GLP-1 fulfillment onto existing infrastructure with no ongoing doctor relationship behind it at all — a different failure mode than the DTC platforms, but the same missing piece. Dose changes also happen on a deliberately slower, more conservative schedule than the manufacturer’s own titration chart, with planned holds along the way — the goal is a controlled pace, not the fastest possible climb.

Before you enter a card number anywhere, check for these:

– Can you name your prescriber? Not “a licensed provider network” — an actual name you could look up. – Does the same person see your chart at your next visit? If your history resets every time you message in, nobody’s actually managing your care. – Is the pharmacy named and licensed? If you can’t find who’s compounding your medication, that’s the answer. – Is the price the price? Ask what it costs at month six, not just month one. – Would a physician reviewing your chart change your dose, or does an algorithm decide it?

If you can’t answer all five, you don’t know if what you’re buying is legit. You know it was easy to buy.

Ready to start? Apply at summitmetabolichealth.com/apply. You can read more of my thinking on this across the Summit blog.

This post is educational and doesn’t replace an individualized medical evaluation. Semaglutide requires a prescription and clinical monitoring; talk with a licensed physician about whether it’s appropriate for you.